Ligand ID: HLZ


Drugbank ID:
DB01275
(Hydralazine)


Indication:
For the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.

Get human targets for HLZ in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'HLZ' AND SARS-RELATED PROTEINS ONLY

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		1xak ORF7A ACCESSORY
PROTEIN
(SARSr-CoV)		4 / 6
PHE A  39
TYR A  25
THR A  59
PHE A  48
1.62A18.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA302_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		4 / 6
LEU B  14
PRO B   8
ARG B  78
HIS B  80
1.69A18.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		2ghw SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
PHE A 325
TYR A 352
VAL A 498
PHE A 501
1.45A20.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		2ghw ANTI-SCFV ANTIBODY,
80R
(Homo
sapiens)		4 / 6
PHE B  68
TYR B  94
VAL B  12
THR B 114
1.80A23.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		2gri NSP3
(SARSr)		4 / 6
PHE A 107
CYH A 105
VAL A  62
PHE A  88
1.28A16.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 6
PHE A  70
VAL A 290
THR A 120
PHE A 156
1.68A21.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		2xyv PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 6
PHE A  70
VAL A 290
THR A 120
PHE A 156
1.66A21.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		4 / 6
PHE A 416
TYR A 367
VAL A 496
THR A 363
1.64A19.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 6
PHE A  70
VAL A 290
THR A 120
PHE A 156
1.70A22.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA302_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		5c8t NSP10
(SARSr-CoV)		4 / 6
LEU A  14
GLU A   6
PRO A   8
ARG A  78
1.38A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA302_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 6
LEU M  14
GLU M   6
PRO M   8
HIS M  80
1.50A17.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		5x4r S PROTEIN
(MERS-CoV)		4 / 6
PHE A 281
VAL A 263
THR A 257
PHE A 254
1.68A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		5x4s SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
PHE A 231
TYR A 252
VAL A  66
PHE A  69
1.79A21.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 6
PHE B 741
TYR B 738
THR A 980
PHE A 952
1.45A12.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		5x5c S PROTEIN
(MERS-CoV)		4 / 6
PHE B 281
VAL B 263
THR B 257
PHE B 254
1.67A12.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
PHE A 741
TYR A 738
THR B 980
PHE B 952
1.36A12.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		6acg ACE2
(Homo
sapiens)		4 / 6
PHE D 512
TYR D 515
VAL D 226
THR D 517
1.79A17.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
PHE B 741
TYR B 738
THR A 980
PHE A 952
1.70A12.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		6crz SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
PHE B  22
VAL B  97
THR B  71
PHE B  76
1.59A12.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		6jyt HELICASE
(SARSr-CoV)		4 / 6
CYH A  19
VAL A  34
THR A  37
PHE A 106
1.59A17.05
 ZN  A 703 (-2.2A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PHE L  41
TYR L  92
VAL H  37
PHE L 103
1.54A21.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		6nur NSP12
(SARSr-CoV)		4 / 6
TYR A 483
CYH A 482
THR A 586
PHE A 480
1.68A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LTW_A_HLZA300_1
(ARYLAMINE
N-ACETYLTRANSFERASE
NAT)		6vw1 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PHE E 429
TYR E 380
VAL E 510
THR E 376
1.69A19.86
None